Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Scholar Rock Holding Corp (NQ: SRRK )

7.975 +0.235 (+3.04%)
Streaming Delayed Price Updated: 2:02 PM EDT, Jul 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Scholar Rock Holding Corp

< Previous 1 2 3 4 5 6 7 Next >
Scholar Rock Announces New SRK-439 Preclinical Data Showing Significant Lean Mass Preservation and Attenuation of Fat Mass Rebound Following GLP-1 Receptor Agonist Withdrawal
From Scholar Rock
Via Business Wire
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock
Via Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Scholar Rock Presents New Data from SRK-181 Phase 1 DRAGON Trial at ASCO 2024 Annual Meeting
From Scholar Rock
Via Business Wire
Scholar Rock to Present New Data from SRK-181 Phase 1 DRAGON Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
From Scholar Rock
Via Business Wire
Scholar Rock Announces Initiation of Phase 2 EMBRAZE Trial of Apitegromab in Obesity and New Preclinical Data Supporting SRK-439 in Obesity
From Scholar Rock
Via Business Wire
Scholar Rock to Participate in Upcoming Investor Conferences
From Scholar Rock
Via Business Wire
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock
Via Business Wire
Scholar Rock to Host Investor Day on May 22, 2024
From Scholar Rock
Via Business Wire
SRRK Stock Earnings: Scholar Rock Holding Misses EPS for Q1 2024
SRRK stock results show that Scholar Rock Holding missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Scholar Rock Reports First Quarter 2024 Financial Results and Highlights Business Progress
From Scholar Rock
Via Business Wire
3 Speculative Weight Loss Drug Stocks to Bet On for Big Gains
These weight loss drug stocks are relatively unknown and brimming with potential following the massive success of Novo Nordisk and Eli Lilly. 
Via InvestorPlace
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock
Via Business Wire
Scholar Rock Is A Potential M&A Target, Its Exploration of Obesity Market Garners Interest: Analyst
Raymond James has initiated coverage on Scholar Rock Holding (NASDAQ:SRRK), supported by the potential value with a couple of key programs utilizing selective myostatin inhibition to  
Via Benzinga
SRRK Stock Earnings: Scholar Rock Holding Misses EPS for Q4 2023
SRRK stock results show that Scholar Rock Holding missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Scholar Rock Reports Full Year 2023 Financial Results and Highlights Business Progress
From Scholar Rock
Via Business Wire
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock, Inc.
Via Business Wire
NIO Reports Upbeat Earnings, Joins Dave, V2X, Riskified And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were lower, with the Dow Jones index falling more than 200 points on Tuesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Scholar Rock to Participate in Upcoming Investor Conferences
From Scholar Rock
Via Business Wire
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock
Via Business Wire
Scholar Rock Announces the Addition of Katie Peng to Its Board of Directors and Promotes Mo Qatanani, Ph.D. to Chief Scientific Officer
From Scholar Rock
Via Business Wire
Scholar Rock Presents New Preclinical Data Demonstrating Potential Benefit of SRK-439 for Healthy Weight Loss Management
From Scholar Rock
Via Business Wire
Scholar Rock Announces Presentation of New Preclinical Data Evaluating SRK-439 in Obesity at Keystone Symposia
From Scholar Rock
Via Business Wire
Scholar Rock Announces FDA Clearance of IND Application to Initiate Phase 2 Proof-of-Concept Trial with Apitegromab to Treat Obesity
From Scholar Rock
Via Business Wire
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock
Via Business Wire
Scholar Rock Provides Corporate Update and Highlights Priorities for 2024
From Scholar Rock, Inc.
Via Business Wire
3 Biotech Stocks at the Forefront of the Quest for Eternal Youth
Biotech stocks targeting longevity could uncover the fountain of youth in coming years, offering a prime investment opportunity today. 
Via InvestorPlace
Scholar Rock to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Scholar Rock
Via Business Wire
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock
Via Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.